

AGE-ADJUSTED YEARS OF POTENTIAL LIFE LOST (YPLL) RATES DUE TO OVARIAN CANCER IN CHILE DURING 2002-2019.

Authors: dos Santos, FM¹, Caputo, M¹, Romero, JF¹. Affiliations: ¹Medical Department, GSK, Santiago, Chile

Background & Aims

Since 2013, Ovarian Cancer (OC) was included in the Chilean Explicit Health Guarantees (GES) program, guaranteeing diagnosis and treatment (1). Advances in treatment and changes in clinical practice may impact on OC mortality. Therefore, the objective of this study was to evaluate the Years of Potential Life Lost (YPLL) due to OC in Chile considering 2002-2019 period.

Methods

Deaths: ICD-10 C56, C57.0, C48.1, C48.2 (2)
Population projection: National Statistics Institute (3).

Age-adjusted YPLL rates/100,000 habitants were estimated for Chile and its 7 most populous regions by using the direct method, applying age-specific rates in a population of interest to a standardized age distribution using the 2022 population as reference and considering 80-year life expectancy.

Postmenopausal women (50-64)

and 3rd age (65-79) were analyzed.

The total period was evaluated and stratified into 2002-2013 (pre-GES) and 2014-2019 (post-GES) and assessed qualitative.

Conclusions

Mean AA-YPLL rates post-GES had an overall decrease. However, in certain regions rising rates were observed in recent years. These results must be further studied to understand the causes and design appropriate public health actions.



YPLL rates due to OC had overall declined. However, certain Chilean regions showed increasing rates in recent years.


EPH248



SCAN ME

Results

Years of Potential Life Lost (considering 80 years as life expectancy)




The highest rate of AA-YPLL are in the post-menopause (50-64y) group due to the highest frequency of death.

Age group	Average AA-YPLL per 100.000 habs		% of Change
	Pre-GES: 2002-2013	Post-GES: 2014-2019	
50-64	44,60	43,22	-3%
65-79	19,08	19,16	0,4%

Postmenopausal and 3rd age AA-YPLL rates description in the 7 most populous Chilean regions. Results are shown as mean Pre-GES vs Post-GES (% of change)


50-64y

POST - GES



65-79y

POST - GES



References:
1. Minister of Health. GES 71. Cáncer de ovario epitelial. [cited 2024 Sep 30]. Available at: <https://auge.minsal.cl/problemasdesalud/index/71>.
2. Minister of Health. Department of Health Statistics and Information. [cited 2024 Sep 30]. Available at: <https://deis.minsal.cl/>.
3. National Institute of Statistics. Population Projections. [cited 2024 Sep 30]. Available at: <https://www.inec.cl/estadisticas/sociales/demografia-y-vitales/proyecciones-de-poblacion>

ISPOR Europe | 17-20 Nov 2024 | Barcelona, Spain

Presenting author: Felipe Moraes dos Santos, felipe.s.moraes@gsk.com

Acknowledgements:
We would like to acknowledge Elif Coskuncay from GSK, London, UK for her inputs in the poster, IglooLab for their support on poster design and OPEN Health Communications for the coordination of the review & approval, which was funded by GSK, in accordance with Good Publication Practice (GPP) guidelines (www.ismpp.org/gpp-2022).

Disclosures:
This study was funded by GSK (study ID: 222625). Felipe Moraes and Milva Caputo are employed by GSK and do not hold financial equities in GSK. Jose Romero is an employee of GSK and holds financial equities in GSK.

